Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Learn how root cause analysis and integrated data prevent hydropower bearing failures, reduce costly downtime, and improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback